Skip to main content

THERAPY ACCELERATION PROGRAM® (TAP)

Strategic Venture Philanthropy Funding Initiative Since 2007

Apply Today

 

LLS TAP® Welcomes Immunitas Therapeutics as Newest Partner Read More

What is TAP?

TAP is a strategic venture philanthropy funding initiative to accelerate high-risk, innovative blood cancer therapeutics and change the standard of care in leukemia, lymphoma, and multiple myeloma.

Since its establishment in 2007, TAP has invested more than $125 million in over 70 projects.

Download TAP Presentation (PDF)

Portfolio

Currently over 20 TAP-supported companies or institutions with assets in active development.

 

TAP Team

Over 50 years of first-hand experience in bringing value to your organization beyond the funding with our critical research insight.

Latest News

Read all about the exciting news and milestone events happening with our current and former TAP partners.

"Funding from leaders like LLS TAP helps fuel the progress of our clinical development program, bringing next-generation treatments that much closer to patients. We're particularly excited to be working with LLS TAP because it gives us access to their deep knowledge of blood cancer and their network of patients and drug development experts."

- Rachel Haurwitz, Ph.D., Co-Founder, President and Chief Executive Officer of Caribou Biosciences

 

Since 2017, three TAP-supported therapies have been approved by the U.S. Food and Drug Administration (FDA):

CPX-351 (Vyxeos®), first approved treatment (an innovative reformulation of two chemotherapies) for patients with certain types of high-risk acute myeloid leukemia (AML) - approved on August 3 2017 with clinical data published in Journal of Clinical Oncology

Axicabtagene ciloleucel (Yescarta®), first CAR T-cell immunotherapy approved for patients with non-Hodgkin lymphoma (NHL) and transformed follicular lymphoma (tFL) - approved on October 18 2017 with clinical data published in Lancet Oncology

Tagraxofusp-erzs (Elzonris®), first approved therapy for children and adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN) - approved on December 21 2018 with clinical data published in New England Journal of Medicine

Currently, there are over 20 TAP-supported companies or institutions with assets in active development, including 5 ongoing or planned registration-enabling clinical studies.

 

“Through our partnership with LLS, we have access to their deep knowledge and expertise in hematologic oncology, and to their extensive physician and patient network. By working together, we can accelerate development of our lead product IO-202, a myeloid checkpoint inhibitor, for AML and CMML and help patients who need new treatment options.”

- Charlene Liao, PhD, Co-Founder, President, and Chief Executive Officer of Immune-Onc Therapeutics

View archived TAP webcasts and programs

How can TAP benefit your company?

Hear what the SVP of Corporate & Business Development of Stemline Therapeutics has to say about TAP and the value created for his company beyond the funding amount. LLS TAP partnered with Stemline in 2013 to support key clinical studies for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

How to Apply

TAP accepts and reviews funding inquiries year round.

Apply Now